热门资讯> 正文

Palvella Therapeutics推出1.5亿美元公开募股

2026-02-25 05:21

Palvella Therapeutics (PVLA) announced the commencement of an underwritten public offering of $150M of its common stock.
The company expects to grant underwriters a 30-day option to purchase up to an additional $22.5M of shares.
All shares in the proposed offering will be sold by Palvella.
Net proceeds are intended to advance development of QTORIN rapamycin and QTORIN pitavastatin programs, as well as for working capital, research and development, and general corporate purposes.

More on Palvella Therapeutics

Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst
Palvella surges on late-stage trial win for lead asset
Adagene, Palvella gain after FDA Fast Track Designations
Seeking Alpha’s Quant Rating on Palvella Therapeutics
Historical earnings data for Palvella Therapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。